Vect-Horus Overview

  • Founded
  • 2005
  • Status
  • Private
  • Employees
  • 37
  • Latest Deal Type
  • Series D
  • Latest Deal Amount
  • $14.2M
Latest Deal Amount
  • Investors
  • 5

Vect-Horus General Information


Developer of a targeted drug delivery system intended to enhance the transport of biotherapeutics across biological barriers. The company is based on the specific design and optimization of molecular vectors that once conjugated to a payload deliver to target cells in the body, thereby enabling healthcare providers to improve therapeutic or diagnostic benefits while minimizing both dose-levels and off-target effects of newly developed molecules.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Primary Office
  • Faculté de la Timone
  • 27 Boulevard Jean Moulin 1er étage aile Verte
  • 13005 Marseille
  • France
+33 04 00 00 00 00

Vect-Horus Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vect-Horus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series D) 01-Dec-2020 $14.2M 000.00 000.00 Completed Generating Revenue
8. Later Stage VC 07-Jun-2018 00.000 000.00 0000 Completed Generating Revenue
7. Later Stage VC 21-Mar-2017 00.000 000.00 0000 Completed Generating Revenue
6. Accelerator/Incubator 00.000 Completed Generating Revenue
5. Angel (individual) 00.000 00.000 Completed Generating Revenue
4. Later Stage VC 15-Dec-2014 00.000 00.000 Completed Generating Revenue
3. Grant 00.000 Completed Startup
2. Later Stage VC 28-May-2013 Completed Startup
1. Later Stage VC 28-May-2011 Completed Startup
To view Vect-Horus’s complete valuation and funding history, request access »

Vect-Horus Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
To view Vect-Horus’s complete cap table history, request access »

Vect-Horus Executive Team (3)

Name Title Board Seat Contact Info
Alexandre Tokay Co-Founder, Chief Executive Officer, President and Chairman
Michel Khrestchatisky Ph.D Co-Founder & Scientific Counsel
Jamal Temsamani Ph.D Director, Drug Development & Corporate & Member of the Management Committee
To view Vect-Horus’s complete executive team members history, request access »

Vect-Horus Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vect-Horus Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CAAP Creation Venture Capital Minority 000 0000 000000 0
Financiere Tuileries Corporation Minority 000 0000 000000 0
Alizee Investment Corporation Minority 000 0000 000000 0
SCR Provence and Corsica Other Minority 000 0000 000000 0
Incubateur Impulse Accelerator/Incubator 000 0000 000000 0
To view Vect-Horus’s complete investors history, request access »